Clinical trial
Risperidone Augmentation for PTSD
NCT00215241 · Duke University, Other · Completed
Key facts
| NCT number | NCT00215241 |
|---|---|
| Title | Risperidone Augmentation for PTSD |
| Official title | Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD |
| Lead sponsor | Duke University, Other |
| Collaborators | Janssen Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Post-Traumatic Stress Disorder |
| Intervention type | Drug |
| Interventions | sertraline and risperidone |
| Enrollment | 80 |
| Start date | Apr 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: